Pulmonary Pasteurellosis in a Patient Treated With Tocilizumab for Rheumatoid Arthritis
Tocilizumab is a monoclonal antibody targeting interleukin 6 receptor and leading to its blockage. Commonly used in rheumatoid arthritis (RA), tocilizumab enhances the risk for infections1 including opportunistic infections.2Pasteurella multocida is carried in the mouth and respiratory tract of various animals. Although several forms of the infection are described, main features of pasteurellosis include septic phlegmon; lymphangitis is common. Pneumonia and sepsis are rarer.3 We report a case of pulmonary pasteurellosis, which has never been described with this treatment.